ZKB REVERSE CONVERTIBLE DEFENSIVE ON WORST OF - ROCHE GS/BRISTOL-MYERS SQUIBB/PFIZER INC Share Price

Certificat

Z0973Z

CH1329108521

Market Closed - Swiss Exchange 16:20:00 17/05/2024 BST
98.44 EUR -0.08% Intraday chart for ZKB REVERSE CONVERTIBLE DEFENSIVE ON WORST OF - ROCHE GS/BRISTOL-MYERS SQUIBB/PFIZER INC
Current month+3.09%
1 month+2.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
17/05/24 98.44 -0.08%
16/05/24 98.52 -0.04%
15/05/24 98.56 +0.05%
13/05/24 98.51 +0.63%

Delayed Quote Swiss Exchange

Last update May 17, 2024 at 04:20 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer ZKB
Z0973Z
ISINCH1329108521
Date issued 23/02/2024
Strike 189.6 CHF
Maturity 23/02/2026 (646 Days)
Parity 1 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 101.1
Lowest since issue 95.49
Spread 5
Spread %0.51%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Certificates
  3. Z0973Z Certificat